The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study

Bian, Xiaoyuan; Xia, Jiafeng; Wang, Kaicen; Wang, Qiangqiang; Yang, Liya; Wu, Wenrui; Li, Lanjuan

doi:10.7150/jca.46584

Cited by 13 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to determine the clinical significance and survival outcome of previous malignancies, as these factors may influence clinical trial design, oncology practice, and treatment decisions. Hypothyroidism has recently been identified as a predisposing factor for the development of liver cancer 21 . However, the role of thyroid cancer in PLC remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database

Liu

Heng

Tian

et al. 2022

Sci Rep

View full text Add to dashboard Cite

To explore the effect of prior thyroid cancer on the survival of primary liver cancer (PLC). Eligible PLC patients were selected from the Surveillance, Epidemiology, and End Results (SEER) database during 2004–2016. Propensity score matching (PSM) was used to create a highly comparable control group that PLC patients without prior thyroid cancer. All PLC patients were divided into three groups based on the survival information: (1) PLC-specific death; (2) death due to other causes; (3) alive. The effect sizes were presented by the corresponding hazard ratio (HR) and 95% confidence intervals (CI). Totally, 142 PLC patients with prior thyroid cancer and 1420 PLC patients without prior thyroid cancer were included. During the follow-up period, 714 (45.71%) PLC patients died of liver cancer while 638 (40.85%) PLC patients were alive. Median survival time for PLC patients was 11.00 months, respectively. PLC patients with prior thyroid cancer have a lower risk of death (HR = 0.64; 95% CI: 0.48–0.86). Subgroup analyses stratified by gender displayed the similar relation in female patients with PLC. Prior thyroid cancer may be a protective factor for liver cancer death in PLC patients, especially in female patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database

Liu

Heng

Tian

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The high prevalence of a cancer history among individuals with a new cancer diagnosis may have important implications for the delivery of cancer treatment and survivorship care. Some reports, including those conducted using SEER data, have documented inferior overall survival among patients with certain cancer types, including breast, prostate, colorectal, uterine, thyroid, melanoma, and bladder, who have a prior cancer diagnosis compared to those without, even after accounting for demographic and tumor characteristics 2‐5 . For patients with these cancer types, prior cancer history may therefore influence decisions surrounding treatment for the newly diagnosed cancer.…”

Section: Discussionmentioning

confidence: 99%

“…An increase in the prevalence of the second or later cancer diagnoses may be consequential for several reasons. Some studies have suggested that, for certain cancer types, overall survival may be significantly lower for patients whose diagnosis is a second‐ or higher‐order primary, relative to those with a first primary cancer diagnosis 2‐5 . As a result, patients with a second or later primary cancer are often excluded from cancer clinical trials on the basis of their cancer history 6 .…”

Section: Introductionmentioning

confidence: 99%

Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers

Anderson

Mayer

Nichols

2021

Cancer

View full text Add to dashboard Cite

BACKGROUND Improvements in cancer survival mean that an increasing number of survivors may live long enough beyond their initial cancer to be diagnosed with additional independent primary cancers. The proportion of newly diagnosed cancers that are second‐ or higher‐order primaries and how this proportion has changed over the past several decades were examined. METHODS Data from the Surveillance, Epidemiology, and End Results (SEER) program were used to identify incident malignant primaries diagnosed between 1975 and 2017. Using the SEER sequence number, the authors tabulated the proportion of all cancers in each calendar year that were second‐ or higher‐order primaries. The average annual percent change (AAPC) was then calculated to assess how this proportion has changed over time. RESULTS Analyses included nearly 4.9 million incident cancers diagnosed during 1975‐2017. The proportion of all cancers that were second‐ or higher‐order increased steadily from 9.77% during 1975‐1984 to 21.03% during 2015‐2017, reflecting an AAPC of 2.41% (95% CI, 2.16%‐2.65%). In 2015‐2017, second‐ or higher‐order cancers were most prevalent among cancers of the bladder (28.79%), followed by lung and bronchus (28.07%), melanoma (27.88%), and leukemia (26.10%). The highest AAPCs over the study period were observed for melanoma (4.05%), leukemia (3.51%), and lung and bronchus (3.36%). CONCLUSIONS The proportion of newly diagnosed cancers that are second‐ or higher‐order has grown rapidly over the past several decades and currently exceeds 20%. Continued monitoring of second and later primaries will be critical for anticipating the future impact on cancer treatment and survivorship care.

show abstract

“…Despite these concerns, for many common malignancies this commonplace exclusion criteria are poorly justi ed. Therefore, there have been some published literatures evaluating the effects of prior malignancy on patients with lung cancer, pancreatic adenocarcinoma, gastric cancer, colorectal cancer, laryngeal cancer, ovarian cancer, and prostate cancer [5][6][7][8][9][10][11][12][13][14][15] . According to 2020 FDA Cancer Clinical Trial Eligibility Criteria, patients with prior or concurrent malignancies of the same or different tumor type whose natural history or treatment does not have the potential to interfere with the safety or e cacy assessment of the investigational drug should generally be eligible for enrollment in clinical trials [16] .…”

Section: Introductionmentioning

confidence: 99%

Medical history of thyroid cancer does not impair prognosis in early breast cancer patients: an analysis study based on SEER database and external cohort

Chen

Shen

2023

Preprint

View full text Add to dashboard Cite

Early breast cancer patients who had a medical history of skin or cervix cancers were presently eligible for clinical trials while few data were available regarding thyroid gland cancer. The study estimated the rate of prior thyroid gland cancer and evaluated its impact on survivals among breast cancer patients. Early invasive breast cancer patients from the SEER database (SEER cohort) between 2010 and 2019 and Ruijin Hospital (Ruijin cohort) during 2009 and 2019 were retrospectively analyzed. Ascian or Pacific Island patients in the SEER cohort (SEER API cohort) were analyzed separately. Chi-square test and multivariate logistic regression analysis were performed to describe the clinical features. Kaplan-Meier analysis and Cox proportional hazards model were used to compare the overall survival (OS) and breast cancer specific survival (BCSS). A total of 136,441 patients from the SEER cohort, 17,183 from the SEER API cohort, and 8,079 from the Ruijin cohort were enrolled, of whom 0.68%, 0.81%, and 1.06% had a medical history of thyroid gland cancer, respectively. Patients with prior thyroid gland cancers were significantly older (51-60 years: OR 1.84, 95% CI 1.46-2.30, P < 0.001; 61-70 years: OR 2.00, 95% CI 1.61-2.50, P < 0.001; > 70 years: OR 1.51, 95% CI 1.18-1.92, P = 0.001) and more likely to be API (OR 1.23, 95% CI 1.03-1.48, P = 0.026) versus other races. Multivariate analysis demonstrated that patients with a history of thyroid gland cancer had comparable OS (SEER: HR 0.87, 95% CI 0.68-1.11, P = 0.257; SEER API: HR 0.53, 95% CI 0.22-1.28, P = 0.159; Ruijin: HR 1.07, 95% CI 0.26-4.29, P = 0.811) and BCSS (SEER: HR 0.72, 95% CI 0.49-1.08, P = 0.117; SEER API: HR ∞, 95% CI ∞-∞, P = 0.878; Ruijin: HR 0.70, 95% CI 0.10-4.98, P = 0.750) versus those without primary malignancies in the three cohorts. There were of a sizable of early breast cancer patients with medical history of thyroid gland cancer, which was related with different races. Prior thyroid gland cancer had no adverse impact on clinical outcomes, indicating possible eligible in further clinical trials.

show abstract

The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study

Cited by 13 publications

References 47 publications

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database

Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers

Medical history of thyroid cancer does not impair prognosis in early breast cancer patients: an analysis study based on SEER database and external cohort

Contact Info

Product

Resources

About